Outcomes of acute rejection after interf
β
Sammy Saab; Denise Kalmaz; Nupoor A. Gajjar; Jonathan Hiatt; Francisco Durazo; S
π
Article
π
2004
π
John Wiley and Sons
π
English
β 229 KB
π 1 views
Interferon alfa has been increasingly used against recurrent hepatitis C (HCV) disease in post-liver transplant (LT) recipients. A serious potential adverse effect is acute rejection. We reviewed our experience using interferonbased therapy (interferon or pegylated interferon with or without ribavir